Nascent Biotech

While the long term goal is to bring PTB to market to treat a variety of such cancers including pancreatic, lung, colon and breast cancer, Nascent’s primary focus is to bring PTB to toward regulatory approval and commercialization for treatment of brain cancer for which there remains an unmet demand for more efficacious treatment than is currently available. ~ @marblearchusa DM us your email if you would like a copy of the research report....or join our mailing list at https://www.nascentbiotech.com/contact-nascent-biotech/

NASCENT BIOTECH COMMENCING ENROLLMENT OF SECOND COHORT IN PHASE 1 HUMAN TRIAL FOR PRIMARY AND METASTATIC BRAIN CANCER June 8, 2021 Nascent Biotech, Inc. (OTCQB:NBIO) (Nascent Biotech, Nascent, or the Company), a clinical-stage biotechnology [...] https://www.nascentbiotech.com/

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab There are significant unmet medical needs in a variety of cancers; Nascent is committed to changing patient expectations in some of the world’s most debilitating cancers...licensing Pritumumab to BioRay for Global therapeutic use will bring this promising treatment to significantly more patients who are in need ~ Sean Carrick, CEO of Nascent Biotech https://www.accesswire.com//Nascent-Biotech-and-BioRay-Pha

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note ...as of April 1, 2021, all preferred shares associated with prior convertible financing instruments have already been converted. Only one convertible note remains open, which will not come due until August 2021. "We continue to advance in our mission to eliminate all remaining dilution risk from prior funding rounds, and our latest note payoff represents a substantial... step in that process," noted Sean Carrick, CEO of Nascent Biotech. "With all prior conversions already effective in our outstanding share supply, and the Harbor Gate note now settled, we have almost entirely eliminated outstanding dilution risk for shareholders." https://www.accesswire.com//Nascent-Biotech-Continues-Anti

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt https://www.accesswire.com//Nascent-Biotech-Announces-Pre- CEO Sean Carrick stated, "We value our shareholders and our reputation as a shareholder friendly Company above all else. We have our sights set on some very big long-term objectives. And we won't get there by working against the interests of our common equity holders.

Patient enrollment remains open, and the trial continues to recruit new patients for participation. Those interested may review trial requirements HERE. "Dosing human cancer patients in our Phase 1 clinical trial is a key milestone on the path toward determining the safety profile of Pritumumab under clinical conditions," noted Nascent CEO Sean Carrick. "This study will also provide fresh insight into PTB's efficacy on primary brain tumors." https://www.accesswire.com//Nascent-Biotech-Announces-Init